JP2005511612A - 塩酸バラシクロビルの無水結晶形 - Google Patents

塩酸バラシクロビルの無水結晶形 Download PDF

Info

Publication number
JP2005511612A
JP2005511612A JP2003542191A JP2003542191A JP2005511612A JP 2005511612 A JP2005511612 A JP 2005511612A JP 2003542191 A JP2003542191 A JP 2003542191A JP 2003542191 A JP2003542191 A JP 2003542191A JP 2005511612 A JP2005511612 A JP 2005511612A
Authority
JP
Japan
Prior art keywords
valaciclovir hydrochloride
anhydrous crystalline
anhydrous
hydrochloride
hydrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003542191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511612A5 (cg-RX-API-DMAC7.html
Inventor
ファイン,ヘレン,エス
ジョーンズ,デイヴィッド,アラン
レイク,フィリップ,ジー.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005511612A publication Critical patent/JP2005511612A/ja
Publication of JP2005511612A5 publication Critical patent/JP2005511612A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003542191A 2001-11-05 2002-10-23 塩酸バラシクロビルの無水結晶形 Pending JP2005511612A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33331301P 2001-11-05 2001-11-05
PCT/US2002/033926 WO2003040145A1 (en) 2001-11-05 2002-10-23 Anhydrous crystal form of valaciclovir hydrochloride

Publications (2)

Publication Number Publication Date
JP2005511612A true JP2005511612A (ja) 2005-04-28
JP2005511612A5 JP2005511612A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=23302261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542191A Pending JP2005511612A (ja) 2001-11-05 2002-10-23 塩酸バラシクロビルの無水結晶形

Country Status (10)

Country Link
US (2) US20040197396A1 (cg-RX-API-DMAC7.html)
EP (1) EP1453834A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005511612A (cg-RX-API-DMAC7.html)
AU (1) AU2002348022B2 (cg-RX-API-DMAC7.html)
CA (1) CA2465420A1 (cg-RX-API-DMAC7.html)
FR (1) FR2831885A1 (cg-RX-API-DMAC7.html)
GB (1) GB2383038B (cg-RX-API-DMAC7.html)
GR (1) GR1004358B (cg-RX-API-DMAC7.html)
IT (1) ITRM20020555A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003040145A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN105753868B (zh) * 2016-04-12 2017-08-01 浙江理工大学 一种盐酸伐昔洛韦的半水合物及其制备方法
CN112176011B (zh) * 2020-10-26 2022-10-18 辰欣药业股份有限公司 一种酶催化制备盐酸伐昔洛韦的方法
CN116754538B (zh) * 2023-06-15 2024-05-07 深圳市新阳唯康科技有限公司 一种阿昔洛韦软膏的晶型定量方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法

Also Published As

Publication number Publication date
GR1004358B (el) 2003-10-07
GB0225771D0 (en) 2002-12-11
US20040197396A1 (en) 2004-10-07
ITRM20020555A0 (it) 2002-11-05
US20070093511A1 (en) 2007-04-26
AU2002348022B2 (en) 2006-06-15
GR20020100478A (el) 2003-07-16
GB2383038B (en) 2005-01-19
CA2465420A1 (en) 2003-05-15
FR2831885A1 (fr) 2003-05-09
GB2383038A (en) 2003-06-18
WO2003040145A1 (en) 2003-05-15
EP1453834A1 (en) 2004-09-08
ITRM20020555A1 (it) 2003-05-06

Similar Documents

Publication Publication Date Title
CA2210799C (en) Valaciclovir hydrochloride in anhydrous crystalline form
AU2002348022B2 (en) Anhydrous crystal form of valaciclovir hydrochloride
AU2002348022A1 (en) Anhydrous crystal form of valaciclovir hydrochloride
JP6870082B2 (ja) 二メシル酸パルボシクリブの固体形態
JP2025138809A (ja) 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶性塩形態
WO2022165141A1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
JP2024054139A (ja) Flna結合化合物及びその塩酸塩の固体多形
WO2018122780A1 (en) Solid state forms of lenvatinib mesylate
WO2025201325A1 (zh) 4-[3-(环丙基甲氧基)-4-(二氟甲氧基)苯乙基]吡啶-2(1h)-酮的固体形式及其制备方法
JP2025514078A (ja) [2-(1h-インドール-3-イル)-1h-イミダゾール-4-イル](3,4,5-トリメトキシフェニル)メタノン及びその塩の多形
JP5666464B2 (ja) 新規化合物
KR100659927B1 (ko) 다형태를갖는독사조신메실레이트의새로운형태(제iii형)
WO2011029005A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
CN110582279B (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
RS20060113A (sr) Stabilni kristalni oblik bifeprunoks mezilata (7-/4-(1,1'- bifenil/-3-il-metil)-1-piperazinil/-2(3h)-benzoksazolon monometansulfonat)
JP2007538087A (ja) 結晶固形ファムシクロビルを調製するための乾燥方法
JP2025128032A (ja) ダプロデュスタットの共結晶
AU2006226625B2 (en) Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lH-pyrrolizin-5-ylacetic acid
HK40054619B (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
EA049155B1 (ru) Калиевая соль 2-[(4s)-8-фтор-2-[4-(3-метоксифенил)пиперазин-1-ил]-3-[2-метокси-5-(трифторметил)фенил]-4н-хиназолин-4-ил]уксусной кислоты
MXPA97005462A (en) Derived from guan
HK1074628A (en) Polymorphs of zaleplon and methods for the preparation thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091124